keyword
https://read.qxmd.com/read/38648995/systematic-review-of-the-efficacy-of-stereotactic-ablative-radiotherapy-for-oligoprogressive-disease-in-metastatic-cancer
#21
REVIEW
Emma Doyle, Angus J Killean, Stephen Harrow, Iain D Phillips
BACKGROUND: Stereotactic Ablative Radiotherapy (SABR) for the treatment of oligometastatic disease can improve survival and delay the requirement for systemic therapy. The benefits of SABR in oligoprogressive disease are less well-defined. Here, we evaluate the available evidence investigating the efficacy of SABR in the treatment of oligoprogressive disease. METHODS: A systematic review was carried out following PRISMA guidelines. Medline and Embase databases were searched using the terms "stereotactic radiotherapy" OR "SABR" OR "Stereotactic Ablative Body Radiotherapy" OR "SBRT" OR "SRT" AND "oligoprogression" in May 2022, June 2023, and February 2024...
April 20, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38648944/editorial-comment-on-major-complications-and-adverse-events-related-to-use-of-spaceoar-hydrogel-for-prostate-cancer-radiotherapy
#22
EDITORIAL
Zachary Klaassen, J Kyle Cline, Rashid K Sayyid
No abstract text is available yet for this article.
April 20, 2024: Urology
https://read.qxmd.com/read/38648657/second-primary-cancers-following-radiotherapy-for-prostate-cancer-how-many-are-actually-due-to-the-radiotherapy
#23
JOURNAL ARTICLE
Scott C Morgan, Mark T Corkum
No abstract text is available yet for this article.
April 2024: Canadian Urological Association Journal
https://read.qxmd.com/read/38648640/effect-of-health-service-area-on-primary-care-physician-provision-of-low-value-cancer-screening
#24
JOURNAL ARTICLE
Kassandra Dindinger-Hill, Joshua Horns, Jacob Ambrose, Jeffrey Vehawn, Mouneeb Choudry, Trevor C Hunt, Jonathan Chipman, Benjamin Haaland, Jiaming Li, Heidi A Hanson, Brock O'Neil
BACKGROUND: Using a health systems approach to investigate low-value care (LVC) may provide insights into structural drivers of this pervasive problem. OBJECTIVE: To evaluate the influence of service area practice patterns on low-value mammography and prostate-specific antigen (PSA) testing. DESIGN: Retrospective study analyzing LVC rates between 2008 and 2018, leveraging physician relocation in 3-year intervals of matched physician and patient groups...
April 23, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38648082/kinesin-facilitates-phenotypic-targeting-of-therapeutic-resistance-in-advanced-prostate-cancer
#25
JOURNAL ARTICLE
Maddison Archer, Diane Begemann, Edgar Gonzalez-Kozlova, Prerna R Nepali, Estefania Labanca, Peter Shepherd, Navneet Dogra, Nora Navone, Natasha Kyprianou
Understanding the mechanisms underlying resistance is critical to improving therapeutic outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Previous work showed dynamic interconversions between epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) defines the phenotypic landscape of prostate tumors, as a potential driver of emergence of therapeutic resistance. In this study, we use in vitro and in vivo preclinical MDA PCa PDX models of resistant human prostate cancer to determine molecular mechanisms of cross-resistance between anti-androgen therapy and taxane chemotherapy, underlying the therapeutically resistant phenotype...
April 22, 2024: Molecular Cancer Research: MCR
https://read.qxmd.com/read/38648061/biomarker-vs-mri-enhanced-strategies-for-prostate-cancer-screening-the-sthlm3-mri-randomized-clinical-trial
#26
JOURNAL ARTICLE
Lars Björnebo, Andrea Discacciati, Ugo Falagario, Hari T Vigneswaran, Fredrik Jäderling, Henrik Grönberg, Martin Eklund, Tobias Nordström, Anna Lantz
IMPORTANCE: Prostate cancer guidelines often recommend obtaining magnetic resonance imaging (MRI) before a biopsy, yet MRI access is limited. To date, no randomized clinical trial has compared the use of novel biomarkers for risk estimation vs MRI-based diagnostic approaches for prostate cancer screening. OBJECTIVE: To evaluate biomarker-based risk estimation (Stockholm3 risk scores or prostate-specific antigen [PSA] levels) with systematic biopsies vs an MRI-enhanced strategy (PSA levels and MRI with systematic and targeted biopsy) for the detection of clinically significant prostate cancer in a screening setting...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38647876/increase-of-prostate-specific-antigen-doubling-time-predicts-survival-in-metastatic-castration-resistant-prostate-cancer-patients-undergoing-radium-therapy
#27
JOURNAL ARTICLE
Hsi-Huei Lu, Nan-Tsing Chiu, Mu-Hung Tsai
OBJECTIVE: Radium-223 (Ra-223) is an important treatment modality for bone-dominant metastatic castration-resistant prostate cancer (mCRPC). However, there is currently a lack of effective markers to monitor treatment response during treatment. We aim to investigate the response in prostate-specific antigen doubling time (PSADT) as a potential marker for assessing Ra-223 treatment in mCRPC patients. METHODS: We retrospectively collected data from mCRPC patients who underwent radium treatment at our institution between August 2020 and June 2023...
April 22, 2024: Annals of Nuclear Medicine
https://read.qxmd.com/read/38647846/cytotoxicity-of-subcritical-water-extracts-obtained-from-byproducts-generated-at-commercial-pecan-shelling-operations-on-cancer-cells
#28
JOURNAL ARTICLE
Canan Sevimli Gur, Nurhan Turgut Dunford, Zinar Pinar Gumus
This study examined potential of the extracts obtained from the byproducts generated at commercial pecan nut-shelling operations in cancer treatment. The subcritical water extracts obtained from two varieties, Native and Pawnee, were analyzed for their phenolic contents and compositions. Effects of the extracts on viability and IC50 of the human cell lines representing a broad range of cancer types, cervical, lung, skin, breast, colon and prostate cancers, were investigated. Although the effect of the temperature on the phenolic contents and compositions of the extracts was not statistically significant, the influence of the variety was extensive...
July 28, 2023: Bioresources and Bioprocessing
https://read.qxmd.com/read/38647728/predicting-contralateral-extraprostatic-extension-in-unilateral-high-risk-prostate-cancer-a-multicentric-external-validation-study
#29
JOURNAL ARTICLE
Romain Diamand, Jean-Baptiste Roche, Vito Lacetera, Giuseppe Simone, Olivier Windisch, Daniel Benamran, Alexandre Fourcade, Georges Fournier, Gaelle Fiard, Guillaume Ploussard, Thierry Roumeguère, Alexandre Peltier, Simone Albisinni
PURPOSE: Accurate prediction of extraprostatic extension (EPE) is crucial for decision-making in radical prostatectomy (RP), especially in nerve-sparing strategies. Martini et al. introduced a three-tier algorithm for predicting contralateral EPE in unilateral high-risk prostate cancer (PCa). The aim of the study is to externally validate this model in a multicentric European cohort of patients. METHODS: The data from 208 unilateral high-risk PCa patients diagnosed through magnetic resonance imaging (MRI)-targeted and systematic biopsies, treated with RP between January 2016 and November 2021 at eight referral centers were collected...
April 22, 2024: World Journal of Urology
https://read.qxmd.com/read/38647689/the-impact-of-mpmri-targeted-vs-systematic-biopsy-on-the-risk-of-prostate-cancer-downgrading-at-final-pathology
#30
JOURNAL ARTICLE
G Sorce, A Stabile, F Pellegrino, E Mazzone, A Mattei, L Afferi, S Serni, A Minervini, M Roumiguiè, B Malavaud, M Valerio, A Rakauskas, G Marra, P Gontero, F Porpiglia, H Guo, J Zhuang, G Gandaglia, F Montorsi, A Briganti
PURPOSE: Although targeted biopsies (TBx) are associated with improved disease assessment, concerns have been raised regarding the risk of prostate cancer (PCa) overgrading due to more accurate biopsy core deployment in the index lesion. METHODS: We identified 1672 patients treated with radical prostatectomy (RP) with a positive mpMRI and ISUP ≥ 2 PCa detected via systematic biopsy (SBx) plus TBx. We compared downgrading rates at RP (ISUP 4-5, 3, and 2 at biopsy, to a lower ISUP) for PCa detected via SBx only (group 1), via TBx only (group 2), and eventually for PCa detected with the same ISUP 2-5 at both SBx and TBx (group 3), using multivariable logistic regression models (MVA)...
April 22, 2024: World Journal of Urology
https://read.qxmd.com/read/38647671/enhancing-surgical-outcomes-accurate-identification-and-removal-of-prostate-cancer-with-b7-h3-targeted-nir-ii-molecular-imaging
#31
JOURNAL ARTICLE
Yaqi Tian, Hongliang Shen, Lingbing Li, Xiaohua Jia, Jin Liu, Zhenhua Hu, Liang Wang, Jie Tian
PURPOSE: One of the main reasons for prostate cancer (PCa) recurrence is the difficulty in identifying and removing cancerous lesions during surgery. Accurately localizing and excising cancerous tissue remains a significant challenge. The second near-infrared window (NIR-II, 1000-1700 nm) fluorescence offers enhanced resolution, a high signal-to-noise ratio, and the potential for deeper tissue penetration. However, this technology is not currently employed for intraoperative imaging of PCa...
April 22, 2024: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/38647131/metabolic-characterization-of-sphere-derived-prostate-cancer-stem-cells-reveals-aberrant-urea-cycle-in-stemness-maintenance
#32
JOURNAL ARTICLE
Yuanyuan Luo, Jiachuan Yu, Zhikun Lin, Xiaolin Wang, Jinhui Zhao, Xinyu Liu, Wangshu Qin, Guowang Xu
Alteration of cell metabolism is one of the essential characteristics of tumor growth. Cancer stem cells (CSCs) are the initiating cells of tumorigenesis, proliferation, recurrence, and other processes, and play an important role in therapeutic resistance and metastasis. Thus, identification of the metabolic profiles in prostate cancer stem cells (PCSCs) is critical to understanding prostate cancer progression. Using untargeted metabolomics and lipidomics methods, we show distinct metabolic differences between prostate cancer cells and PCSCs...
April 22, 2024: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/38647107/-prostate-cancer-diagnostics-and-screening
#33
JOURNAL ARTICLE
Rebecka Arnsrud Godtman, Ola Bratt, Tobias Nordström, Jonas Wallström, Jonas Hugosson
Prostate-specific antigen (PSA) based screening is controversial, even though randomised trials show that screening can reduce prostate cancer mortality. The main reason is that screening leads to overdiagnosis of indolent cancers that would never have surfaced clinically in the absence of screening. Recently, several large studies have shown that magnetic resonance imaging (MRI) improves prostate cancer diagnostics. With MRI, up to half of all men with elevated PSA values can be spared a biopsy. When a biopsy is needed, the needles can be directed towards the suspicious area in the prostate, which increases the detection of clinically significant tumors...
April 22, 2024: Läkartidningen
https://read.qxmd.com/read/38647078/precise-prostate-cancer-diagnosis-using-fluorescent-nanoprobes-for-detecting-psa-and-psma-in-serum
#34
JOURNAL ARTICLE
Mingyi Ouyang, Ming Jia, Zixuan Chang, Yinian Wang, Keyi Wang, Xiaonan Gao, Bo Tang
Novel Au-Se bond-based nanoprobes were designed for concurrent detection of PSA and PSMA in serum samples, aiming to enhance the early diagnosis of prostate cancer. These probes demonstrate robust stability, specificity and accuracy, underscoring their potential as non-invasive tools for diagnosis.
April 22, 2024: Chemical Communications: Chem Comm
https://read.qxmd.com/read/38647021/repurposing-of-antifungal-drug-flucytosine-flucytosine-cocrystals-for-anticancer-activity-against-prostate-cancer-targeting-apoptosis-and-inflammatory-signaling-pathways
#35
JOURNAL ARTICLE
Manimurugan Kanagavel, Rajan Marystella Sparjan Samuvel, Vaikundamoorthy Ramalingam, Sunil Kumar Nechipadappu
This study aimed to repurpose the antifungal drug flucytosine (FCN) for anticancer activity together with cocrystals of nutraceutical coformers sinapic acid (SNP) and syringic acid (SYA). The cocrystal screening experiments with SNP resulted in three cocrystal hydrate forms in which two are polymorphs, namely, FCN-SNP F-I and FCN-SNP F-II, and the third one with different stoichiometry in the asymmetric unit (1:2:1 ratio of FCN:SNP:H2 O, FCN-SNP F-III). Cocrystallization with SYA resulted in two hydrated cocrystal polymorphs, namely, FCN-SYA F-I and FCN-SYA F-II...
April 22, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38646849/network-pharmacology-and-molecular-docking-based-strategy-for-predicting-anti-tumour-mechanism-of-linarin
#36
JOURNAL ARTICLE
Jun Wang, Jingjing Cheng
The aim was to explore the anti-tumour mechanism of linarin (LIN) based on network pharmacology and molecular docking. PharmMapper database and GeneCards database were used to screen anti-tumour related targets of LIN. Enrichment analysis of GO and KEGG was conducted to predict the key targets and pathways. At last, LIN was docked with the key targets. ESR1, ESR2, EGFR, AR, TGFBR2, F2, MAPK10, MAPK14, CDK2 and HSP90AA1 were identified as the key targets. The key pathways included pathways in cancer, prostate cancer, pancreatic cancer and breast cancer...
April 22, 2024: Natural Product Research
https://read.qxmd.com/read/38646786/the-effect-of-baseline-o-2-conditions-on-the-response-of-prostate-cancer-cells-to-hypoxia
#37
JOURNAL ARTICLE
Ricardo Alva, Jacob E Wiebe, Jeffrey A Stuart
The transcriptional response to hypoxia is largely regulated by the hypoxia-inducible factors (HIFs), which induce the expression of genes involved in glycolysis, angiogenesis, proliferation, and migration. Virtually all cell culture-based hypoxia experiments have used near-atmospheric (18% O2 ) oxygen levels as baseline for comparison to hypoxia. However, this is hyperoxic compared to mammalian tissue microenvironments, where oxygen levels range from 2-9% O2 (physioxia). Thus, these experiments actually compare hyperoxia to hypoxia...
April 22, 2024: American Journal of Physiology. Cell Physiology
https://read.qxmd.com/read/38646707/racial-and-ethnic-disparities-in-prostate-cancer-screening-following-the-2018-us-preventive-services-task-force-recommendation-statement
#38
JOURNAL ARTICLE
Nathan VanderVeer-Harris, Zachary D Zippi, Dev P Patel, Murugesan Manoharan, Jorge R Caso, Georgeta D Vaidean
OBJECTIVE: In 2018, the United States Preventive Services Task Force promoted shared decision making between healthcare provider and patient for men aged 55 to 69. This study aimed to analyze rates of prostate-specific antigen (PSA) testing across racial and ethnic groups following this new recommendation. METHODS: A secondary analysis was conducted of the 2020-2021 Behavioral Risk Factor Surveillance System database to assess men aged 55 or older without a history of prostate cancer...
April 22, 2024: Journal of Medical Screening
https://read.qxmd.com/read/38646643/exploring-the-role-of-combined-external-beam-radiotherapy-and-targeted-radioligand-therapy-with-177-lu-lu-psma-617-for-prostate-cancer-from-bench-to-bedside
#39
JOURNAL ARTICLE
Daria Arbuznikova, Aikaterini Klotsotyra, Lisa Uhlmann, Lisa-Charlotte Domogalla, Nils Steinacker, Michael Mix, Gabriele Niedermann, Simon K B Spohn, Martin T Freitag, Anca L Grosu, Philipp T Meyer, Christian Gratzke, Matthias Eder, Constantinos Zamboglou, Ann-Christin Eder
Management of prostate cancer (PC) might be improved by combining external beam radiotherapy (EBRT) and prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with lutetium-177 (177 Lu)-labeled PSMA inhibitors. We hypothesized a higher efficacy of the combination due to augmentation of the radiation dose to the tumor and interactions of EBRT with PSMA expression potentially increasing radiopharmaceutical uptake. Therefore, this study analyzed the influence of radiation on PSMA expression levels in vitro ...
2024: Theranostics
https://read.qxmd.com/read/38646557/toward-a-new-personalized-psycho-social-approach-for-the-support-of-prostate-cancer-and-their-caregivers-dyads-a-pilot-study
#40
JOURNAL ARTICLE
Clizia Cincidda, Silvia Francesca Maria Pizzoli, Serena Oliveri, Paolo Guiddi, Gabriella Pravettoni
INTRODUCTION: Prostate cancer patients (PCP) often struggle with a significant emotional, physical, and social burden during the care-flow pathway. Noteworthy, PCP should not be considered a standalone patient, but someone who is connected with a relevant social environment and that is usually supported by a beloved one, the caregiver. The involvement of the caregivers through the care pathway might bring significant benefits both on the psychological and the treatment and decision-making side...
2024: Frontiers in Medicine
keyword
keyword
110260
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.